X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (199) 199
science & technology (199) 199
humans (195) 195
cardiovascular system & cardiology (167) 167
cardiac & cardiovascular systems (163) 163
male (155) 155
female (149) 149
medical and health sciences (143) 143
medicin och hälsovetenskap (143) 143
clinical medicine (119) 119
middle aged (118) 118
aged (117) 117
klinisk medicin (117) 117
cardiac and cardiovascular systems (113) 113
kardiologi (113) 113
adult (79) 79
prognosis (57) 57
risk factors (57) 57
congenital heart disease (54) 54
health sciences (53) 53
hälsovetenskaper (53) 53
abridged index medicus (52) 52
mortality (45) 45
electrocardiography (44) 44
myocardial infarction (44) 44
treatment outcome (43) 43
cardiovascular disease (40) 40
myocardial infarction - mortality (38) 38
myocardial infarction - drug therapy (35) 35
aged, 80 and over (34) 34
follow-up studies (34) 34
myocardial infarction - diagnosis (33) 33
nursing (33) 33
sweden - epidemiology (33) 33
heart diseases (32) 32
cardiovascular (31) 31
congenital (31) 31
omvårdnad (31) 31
vectorcardiography (31) 31
quality of life (30) 30
adults (29) 29
analysis (29) 29
cardiology (29) 29
drug therapy (29) 29
adult congenital heart disease (28) 28
young adult (28) 28
acute myocardial infarction (27) 27
epidemiology (27) 27
heart attacks (27) 27
heart (25) 25
patients (25) 25
time factors (25) 25
prospective studies (24) 24
genetic disorders (23) 23
risk assessment (23) 23
hypertension (22) 22
retrospective studies (22) 22
sweden (22) 22
thrombolytic therapy (22) 22
adolescent (21) 21
cardiac patients (21) 21
diagnosis (21) 21
heart attack (21) 21
heart defects (21) 21
double-blind method (20) 20
heart failure (20) 20
care and treatment (19) 19
congenital diseases (19) 19
folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi (19) 19
myocardial infarction - therapy (19) 19
public health, global health, social medicine and epidemiology (19) 19
myocardial infarction - physiopathology (18) 18
prevalence (18) 18
registries (18) 18
incidence (17) 17
medicin (17) 17
nursing science (17) 17
vårdvetenskap (17) 17
general & internal medicine (16) 16
research (16) 16
stroke (16) 16
heart defects, congenital - epidemiology (15) 15
medicine (15) 15
medicine, general & internal (15) 15
patient outcomes (15) 15
secondary prevention (15) 15
surgery (15) 15
acute coronary syndromes (14) 14
angioplasty (14) 14
coronary artery disease (14) 14
coronary vessels (14) 14
medical research (14) 14
peripheral vascular disease (14) 14
population (14) 14
survival rate (14) 14
age factors (13) 13
cardiovascular diseases (13) 13
clinical trials (13) 13
health aspects (13) 13
hospitals (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Heart Journal, ISSN 0002-8703, 2010, Volume 160, Issue 2, pp. 322 - 328
Journal Article
The New England journal of medicine, ISSN 1533-4406, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Index Medicus | Abridged Index Medicus | Klinisk medicin | Clinical Medicine
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2018, Volume 71, Issue 11, pp. A530 - A530
Journal Article
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1591 - 1599
IMPORTANCE: p38 Mitogen-activated protein kinase (MAPK)–stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Myocardial Infarction - mortality | Humans | Middle Aged | Male | Secondary Prevention | Cyclopropanes - adverse effects | Protein Kinase Inhibitors - adverse effects | Cyclopropanes - therapeutic use | Pyridines - adverse effects | Treatment Failure | Female | C-Reactive Protein - analysis | Myocardial Infarction - enzymology | Pyridines - therapeutic use | Double-Blind Method | Drug Administration Schedule | Myocardial Ischemia - prevention & control | Hospitalization | Myocardial Revascularization | Algorithms | Myocardial Infarction - drug therapy | Protein Kinase Inhibitors - therapeutic use | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Aged | Myocardial Ischemia - surgery | Clinical trials | Care and treatment | Usage | Dosage and administration | Extracellular signal-regulated kinases | Heart attack | Patient safety | Inhibitor drugs | Heart attacks | Clinical outcomes | Index Medicus | Abridged Index Medicus | Pyridines/adverse effects/therapeutic use | Cyclopropanes/adverse effects/therapeutic use | C-Reactive Protein/analysis | Klinisk medicin | Clinical Medicine | p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors | Myocardial Ischemia/prevention & control/surgery | Protein Kinase Inhibitors/adverse effects/therapeutic use | Myocardial Infarction/drug therapy/enzymology/mortality
Journal Article
by Thygesen, Kristian and Alpert, Joseph S and White, Harvey D and Biomarker Group: Allan S. Jaffe, Coordinator (USA), Fred S. Apple (USA), Marcello Galvani (Italy), Hugo A. Katus (Germany), L. Kristin Newby (USA), Jan Ravkilde (Denmark) and ECG Group: Bernard Chaitman, Co-ordinator (USA), Peter M. Clemmensen (Denmark), Mikael Dellborg (Sweden), Hanoch Hod (Israel), Pekka Porela (Finland) and Global Perspective Group: Philip A. Poole-Wilson, Coordinator (UK), Enrique P. Gurfinkel (Argentina), José-Luis Lopez-Sendon (Spain), Prem Pais (India), Shanti Mendis (Switzerland), Jun-Ren Zhu (China) and ESC COMMITTEE FOR PRACTICE GUIDELINES and Implementation Group: Lars C. Wallentin Coordinator (Sweden), Francisco Fernández-Avilés (Spain), Kim M. Fox (UK), Alexander N. Parkhomenko (Ukraine), Silvia G. Priori (Italy), Michal Tendera (Poland), Liisa-Maria Voipio-Pulkki (Finland) and Imaging Group: Richard Underwood, Coordinator (UK), Jeroen J. Bax (The Netherlands), George A. Beller (USA), Robert Bonow (USA), Ernst E. Van Der Wall (The Netherlands) and Joao Morais, Review Coordinator (Portugal), Sorin Brener (USA), Robert Harrington (USA), David Morrow (USA), Udo Sechtem (Germany), Michael Lim (Singapore), Marco A. Martinez-Rios (Mexico), Steve Steinhubl (USA), Glen N. Levine (USA), W. Brian Gibler (USA), David Goff (USA), Marco Tubaro (Italy), Darek Dudek (Poland), Nawwar Al-Attar (France) and Alec Vahanian, Chair (France), A. John Camm (UK), Raffaele De Caterina (Italy), Veronica Dean (France), Kenneth Dickstein (Norway), Gerasimos Filippatos (Greece), Christian Funck-Brentano (France), Irene Hellemans (The Netherlands), Steen Dalby Kristensen (Denmark), Keith McGregor (France), Udo Sechtem (Germany), Sigmund Silber (Germany), Michal Tendera (Poland), Petr Widimsky (Czech Republic), José Luis Zamorano (Spain) and TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), Joseph S. Alpert (USA), Harvey D. White (New Zealand) and Intervention Group: Jean-Pierre Bassand, Co-ordinator (France), William Wijns, Coordinator (Belgium), T. Bruce Ferguson (USA), Philippe G. Steg (France), Barry F. Uretsky (USA), David O. Williams (USA) and Clinical Investigation Group: Paul W. Armstrong, Coordinator (Canada), Elliott M. Antman (USA), Keith A. Fox (UK), Christian W. Hamm (Germany), E. Magnus Ohman (USA), Maarten L. Simoons (The Netherlands) and DOCUMENT REVIEWERS and ESC ACCF AHA WHF Task Force and Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction and Sahlgrenska akademin and Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin and Institute of Medicine, Department of Emergeny and Cardiovascular Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
Circulation (New York, N.Y.), ISSN 1524-4539, 11/2007, Volume 116, Issue 22, pp. 2634 - 2653
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2008, Volume 358, Issue 15, pp. 1547 - 1559
This large trial compared the angiotensin-receptor blocker telmisartan, the angiotensin-converting–enzyme inhibitor ramipril, and combination therapy with both... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Risk | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Diabetes Mellitus - drug therapy | Kaplan-Meier Estimate | Hospitalization | Creatinine - blood | Angioedema - chemically induced | Aged | Complications and side effects | Ramipril | Drug therapy, Combination | Diabetes | Cardiovascular diseases | Drug therapy | Comparative analysis | Risk factors | Telmisartan | Clinical trials | Vein & artery diseases | Cardiovascular disease | Pharmacology | Clinical outcomes | Index Medicus | Abridged Index Medicus | Blood Pressure | Benzimidazoles | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | epidemiology | Angiotensin-Converting Enzyme Inhibitors | Combination | MEDICAL AND HEALTH SCIENCES | Creatinine | chemically induced | Benzoates | drug therapy | Angioedema | drug effects | Diabetes Mellitus | blood | adverse effects | mortality | therapeutic use | Kaplan-Meiers Estimate
Journal Article